Contents © Peter Wittner, Interpharm Consultancy 2020
Interpharm is an agent for Cliantha (formerly BA Research), India which provides low cost, high quality bioequivalence and Phase I -
We are working together to provide clients with a first class service at competitive prices -
For information about Cliantha’s clinical trial experience with Generics and Biosimilars, please clcik on the logo above.
Following its acquisition of Hill Top, a CRO based in the USA and Canada serving the Dermatology Rx and Personal Healthcare industry, Cliantha can also carry out studies at American sites where a client needs to conduct an American study for regulatory or marketing purposes.
All pharmaceutical companies need to find savings in their development budget and one safe way to do this is to entrust your Phase I, bioequivalence and biosimilarity studies to Cliantha Research.
Cliantha can offer:
Consider the particular advantages to working with Cliantha Research relative to other CROs:
Cliantha’s study prices in India are significantly lower than those of major competitors in Western or Eastern Europe or North America while still complying with GCP and GLP requirements.
Dr, Chirag Shah is extremely responsive and can give you a more personal service than bigger, more expensive CROs with fast turnaround time on studies once commissioned.
The company, based in Ahmedebad in the state of Gujarat in India, was founded in 2004 with a 100-
Cliantha has a client base that includes a variety of international clients across Europe and North America. Cliantha Research has now completed studies on several hundred substances with validated analytical methods for all of them. These have covered a variety of oral and topical dosage forms and we should be able to help you with advice on studies on any type of formulation.
With regular flights to Ahmedabad from all parts of India and journey times of around one hour from Mumbai, the clinic is easily accessible from most parts of the UK and Europe.
Click on the logo below to download a PDF summary about the experience of Cliantha Research in Generic, Biosimilar and Phase I-
|Conferences and training|
|Article 01 - some thoughts about Podcasts|
|Bioequivalence, Phase I-IV studies|